Biomarin Pharmaceutical

Biomarin Pharmaceutical

BMRN· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -9.6% in FY2025

Alexander Hardy is the CEO of Biomarin Pharmaceutical and was paid $21.9M in FY2025 (Dec), up 48%.

Pay$100 in the stock at the end of FY22 → $57
CEO pay is from each Biomarin Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Alexander HardyFY2025
  2. 2Gregory R. Friberg, M.D.FY2025
  3. 3Brian R. MuellerFY2025
  4. 4Cristin HubbardFY2025
  5. 5C. Greg Guyer, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Biomarin Pharmaceutical paid its 5 named executives $47.3M in total in FY2025 (Dec). CEO Alexander Hardy was paid $21.9M of that.

Name
Alexander HardyPresident and CEO
Gregory R. Friberg, M.D.Executive Vice President, Chief Research & Development OfficerNot disclosed
Brian R. MuellerExecutive Vice President, CFO
Cristin HubbardExecutive Vice President, Chief Commercial OfficerNot disclosed
C. Greg Guyer, Ph.D.Executive Vice President, Chief Technical Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers14

See all

The FY2025 (Dec) proxy of Biomarin Pharmaceutical names 14 peer companies for pay. Among Biomarin Pharmaceutical and these peers, CEO pay was 4th highest of 9 and total shareholder return was the lowest of 9.

4th highest of 9in Biomarin Pharmaceutical and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

9th highest of 9in Biomarin Pharmaceutical and its pay peers, FY2025 (Dec) by total shareholder return:

$68$321

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Richard A. MeierChair · 18 yr on the boardIndependentTransactions and Strategy (Chair)—Paid as an executive
  • Timothy P. WalbertDirector · -1 yr on the boardIndependent—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Pay
    Biomarin Pharmaceutical CTO pay rose 13% to $5.7M. The stock fell 10% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Biomarin Pharmaceutical CTO pay fell 11% to $5.1M. The stock fell 32% in FY2024 (Dec).
    DEF 14A
  3. Pay
    Biomarin Pharmaceutical Division head pay fell 18% to $5.7M. The stock fell 10% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Biomarin Pharmaceutical CFO pay rose 24% to $6.8M. The stock fell 10% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Biomarin Pharmaceutical CEO pay rose 48% to $21.9M. The stock fell 10% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Biomarin Pharmaceutical Division head pay fell 16% to $8.1M. The stock fell 32% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Biomarin Pharmaceutical General counsel pay fell 10% to $4.6M. The stock fell 7% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Biomarin Pharmaceutical CFO pay rose 13% to $5.5M. The stock fell 32% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Biomarin Pharmaceutical CEO pay fell 17% to $14.9M. The stock fell 32% in FY2024 (Dec).
    DEF 14A
  10. Board
    Timothy P. Walbert joined the board of Biomarin Pharmaceutical. Timothy P. Walbert now sits on 5 public boards.
    3
  11. Pay
    Biomarin Pharmaceutical Director pay rose 20% to $22.0M. The stock fell 7% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Biomarin Pharmaceutical Division head pay rose 11% to $9.7M. The stock fell 7% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Biomarin Pharmaceutical Division head pay rose 26% to $8.7M. The stock rose 17% in FY2022 (Dec).
    DEF 14A
  14. Pay
    Biomarin Pharmaceutical CTO pay rose 12% to $5.7M. The stock fell 7% in FY2023 (Dec).
    DEF 14A
  15. Board
    Athena Countouriotis joined the board of Biomarin Pharmaceutical. Athena Countouriotis sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 21, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 8, 2025FY2024
Annual report10-KFeb 24, 2025FY2024
Proxy statementDEF 14AApr 9, 2024FY2023
Annual report10-KFeb 26, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data